APOB and metabolic syndrome: Moreover, the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for the management of dyslipidemias have defined secondary goals for both non-HDL-C and ApoB to help guide lipid-lowering therapy adjustments after the achievement of an LDL-C goal [5].